Vitality Watch

Dossier pubmed preclinical 01-aug-2026
Animal model, organoid, or cell-culture result — not yet human

The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.

Key claim: Melatonin downregulates p16Ink4a and upregulates OCT4 via the vitamin D receptor (VDR), linking anti-senescence and stemness pathways and supporting osteogenic differentiation in cell models.

Abstract

Melatonin is a multifunctional indole hormone with established roles in anti-aging and tissue regeneration. Although it has been shown to modulate key senescence-associated markers such as p16Ink4a (p16) and OCT4, the underlying molecular mechanisms remain incompletely understood. MC3T3-E1 cells were treated with melatonin to evaluate its effects on p16 and OCT4 expression using Western blot and RT-qPCR. Isothermal titration calorimetry (ITC) and molecular docking were employed to investigate protein-protein interactions and structural binding patterns. VDR knockdown experiments were performed to assess functional causality. In addition, osteogenic differentiation was evaluated in bone marrow-derived mesenchymal stem cells (BMSCs) using alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining. Melatonin significantly downregulated p16 and upregulated OCT4 expression without affecting cell viability. ITC analysis revealed that melatonin does not directly bind to p16 or OCT4, but both proteins interact with the vitamin D receptor (VDR) with moderate affinity. Molecular docking further supported stable binding conformations between VDR and p16/OCT4. Functionally, VDR knockdown disrupted the balance of p16 and OCT4 expression and impaired osteogenic differentiation, as evidenced by decreased ALP activity and reduced mineralized nodule formation. These findings identify VDR as a critical mediator of melatonin signalling and reveal a novel VDR-centered regulatory axis linking senescence and stemness pathways. This mechanism provides new insights into the anti-senescence and pro-regenerative effects of melatonin and suggests potential therapeutic strategies for aging-related diseases such as osteoporosis.

Why this matters

Melatonin is already a heavily-pitched anti-aging molecule, and this study nominates a specific VDR-mediated route by which it might suppress the senescence marker p16Ink4a while re-elevating the pluripotency factor OCT4 — a rare mechanistic bridge between senescence biology and stemness/reprogramming pathways. The finding stays at the cell-culture tier: it sharpens the causal diagram without demonstrating that melatonin reduces senescent-cell burden or improves tissue function in animals or humans.

Source

Link

Briefing card

The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.
Stage: preclinical · pubmed · 01-aug-2026

Melatonin downregulates p16Ink4a and upregulates OCT4 via the vitamin D receptor (VDR), linking anti-senescence and stemness pathways and supporting osteogenic differentiation in cell models.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/jcmm.71321

build build 880 · 2bcef25 · 2026-11-18